



The United States Patent and Trademark Office

1617
RECEIVED
DEC 20 2002

In re Application of:

Assignee: University of Southern California

Inventor: Laurie DeLeve

Application No: 10/086,072

Filed: 02/27/2002

For: **COMPOSITION AND METHOD FOR
PREVENTING AND TREATING
SINUSOIDAL OBSTRUCTION
SYNDROME AND RADIATION-
INDUCED LIVER DISEASE**

Group Art Unit: 1617

Examiner: Bahar, Mojdeh

Certificate of Mailing Under 37 C.F.R. § 1.8

Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: December 11, 2002

Type or Print Name: Bernice E. Worley

Signature

Bernice E. Worley

TECH CENTER 1600/2900
#7/B
3/25/03

SUPPLEMENTAL AMENDMENT AND RESPONSE TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This paper is filed as a supplement to the reply to the Office Action filed December 9, 2002 with the U.S. Patent and Trademark Office on August 9, 2002, in connection with the above-identified patent application.

AMENDMENTS

IN THE CLAIMS:

Please AMEND claims 10 as follows:

B1
10. (Twice Amended) The method of claims 1 or 2, wherein said matrix metalloproteinase inhibitor is Marimastat, Prinomastat, RS-130,830, (N-hydroxy-2(R)-[[4-methoxysulfonyl](3-picolyl) amino]-3-methylbuteamide hydrochloride) monohydrate, Solimastat, BAY 12-9566, (3(R)(cyclopentylmethyl)-2(R)-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid), BMS-272591, Ilomastat, D2163, Metastat, Neovastat, or Periostat.

Attached hereto is a marked-up version of the changes made to the claims. The attached pages are captioned "Version with Markings to Show Changes Made".